TOKYO, January 19, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Science Based Targets initiative (SBTi)*1 has validated and approved its greenhouse gas (GHG) emissions reduction targets. The targets, as a science-based initiative, have been approved towards achieving the 1.5 degrees Celsius and well-below 2 degrees Celsius targets of the Paris Climate Agreement.
Astellas has set "Deepen our engagement in sustainability" as one of the strategic goals in its Corporate Strategic Plan 2021. The reduction of environmental burden is Astellas' priority themes within sustainability.
“For society and Astellas to continue to grow sustainably, we recognize that we need to be conscious of the issues affecting our planet and climate change,” said Kenji Yasukawa, President and CEO, Astellas. “Climate change is one of our key issues to address. SBTi certification represents significant progress on environmental sustainability for us under our Corporate Strategic Plan 2021, and we are determined to achieve these goals.”
Astellas’ revised targets are as follows:
- Astellas commits to reduce absolute scope 1 and 2*2 GHG emissions by 63% by FY2030 from the FY2015 base year. <1.5 degrees Celsius target>
- Astellas also commits to reduce absolute scope 3*2 GHG emissions by 37.5% by FY2030 from the FY2015 base year. <Well-below 2 degrees Celsius target>
For more information on specific initiatives, please visit our website.
Astellas continues to further promote sustainability activities and expand information disclosure under its basic policy, which is to improve the sustainability of both the global society and Astellas while keeping ESG [environmental (E), social (S), governance (G)] in mind.
Click below for a copy of the full press release
